SCHEMBL3020801

SCHEMBL3020801

COc1cc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc(OC)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.40
F2RL3 Q96RI0 1/20 0.40
KCNQ1 P51787 1/20 0.38
GPR6 P46095 2/20 0.38
RAB9A P51151 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KDM1A O60341 2/20 0.37
MAOA P21397 2/20 0.37
MAPT P10636 8/20 0.37
ALDH1A1 P00352 5/20 0.37
LMNA P02545 4/20 0.37
HSD17B10 Q99714 3/20 0.37
HPGD P15428 1/20 0.37
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ALOX12 P18054 1/20 0.36
TP53 P04637 3/20 0.36
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3023516 0.94 MAPT (0.42) F2F2RL3KCNQ1GPR6RAB9A
SCHEMBL3010954 0.93 KCNQ1 (0.42) F2F2RL3KCNQ1GPR6RAB9A
SCHEMBL3011323 0.92 RAB9A (0.35) F2F2RL3GPR6RAB9ASMN1; SMN2
SCHEMBL3009031 0.90 PSEN1 (0.36) F2F2RL3KCNQ1RAB9ASMN1; SMN2
SCHEMBL3013306 0.90 RAB9A (0.42) RAB9ASMN1; SMN2MAPTALDH1A1MEN1
SCHEMBL3009020 0.90 USP2 (0.41) F2F2RL3KCNQ1GPR6RAB9A
SCHEMBL3016716 0.90 GPR6 (0.38) F2F2RL3GPR6RAB9ASMN1; SMN2
SCHEMBL3014493 0.90 MAPT (0.42) F2RL3KCNQ1GPR6RAB9ASMN1; SMN2
SCHEMBL3010085 0.89 MAPT (0.43) F2F2RL3GPR6MAPTALDH1A1
SCHEMBL3014057 0.89 MAPT (0.37) F2F2RL3GPR6RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA F2 4807/4885F2RL3 3732/4885KCNQ1 2702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.